Literature DB >> 23537459

Adherence to evidence-based therapies after acute coronary syndrome: a retrospective population-based cohort study linking hospital, outpatient, and pharmacy health information systems in Valencia, Spain.

Gabriel Sanfélix-Gimeno1, Salvador Peiró, Inma Ferreros, Raquel Pérez-Vicente, Julián Librero, Ferrán Catalá-López, Francisco Ortiz, Vicent Tortosa-Nácher.   

Abstract

BACKGROUND: Pharmacological secondary prevention in patients after an acute coronary syndrome (ACS) has contributed substantially to reductions in cardiovascular morbidity and mortality and, overall, has undergone important improvements in recent years. Nevertheless, there is still a considerable adherence gap and opportunity for improvement.
OBJECTIVE: To assess, in a cohort of patients who survived an ACS, adherence to commonly prescribed secondary prevention drugs, factors associated to adherence, and variations among health care delivery areas.
METHODS: We combined the medical and pharmacy databases from a regional public health service in Valencia, Spain, to construct a population-based cohort of patients discharged alive after an emergency admission for an ACS to any hospital of the Valencia Health Agency in 2008. We evaluated medication adherence by determining the proportion of days covered (PDC) for each therapeutic group (antiplatelet agents, beta-blockers, angiotensin antagonists, and statins) in the 9 months following hospital discharge. Fully adherent patients were defined as those having enough treatment to cover 75% (PDC75) of the follow-up period.
RESULTS: The study cohort consisted of 7,462 patients. PDC75 was reached by 69.9% of patients taking antiplatelet agents, 43.3% taking beta-blockers, 45.4% taking angiotensin antagonists, and 58.8% taking statins. Approximately 18% of patients did not reach PDC75 with any treatment, while 47.6% did so for 3 or more therapeutic groups. Lower adherence was found in diagnoses other than myocardial infarction. Other factors associated with nonadherence were older age, women, having copayment, foreign born, and most comorbidities (except for hypertension and hyperlipidemia, which were inversely associated, and diabetes and peripheral disease, which were not significantly associated). Health care delivery areas showed certain variability in their performance on these adherence measures that remained after the adjustment for covariates, although confidence intervals overlapped except between areas at the extremes.
CONCLUSIONS: The proportion of fully adherent patients remains suboptimal, and important improvements are still possible in secondary prevention of ischemic heart disease. The combination of electronic health information systems may be very useful for monitoring adherence and evaluating the effectiveness of adherence and other quality improvement interventions.

Entities:  

Mesh:

Year:  2013        PMID: 23537459     DOI: 10.18553/jmcp.2013.19.3.247

Source DB:  PubMed          Journal:  J Manag Care Pharm        ISSN: 1083-4087


  22 in total

1.  Medication non-adherence after myocardial infarction: an exploration of modifying factors.

Authors:  Matthew J Crowley; Leah L Zullig; Bimal R Shah; Ryan J Shaw; Jennifer H Lindquist; Eric D Peterson; Hayden B Bosworth
Journal:  J Gen Intern Med       Date:  2015-01       Impact factor: 5.128

Review 2.  Medication adherence in patients with diabetes and dyslipidemia: associated factors and strategies for improvement.

Authors:  Lucas N Marzec; Thomas M Maddox
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

3.  Does age modify the relationship between adherence to secondary prevention medications and mortality after acute myocardial infarction? A nested case-control study.

Authors:  Jacopo Lenzi; Paola Rucci; Ilaria Castaldini; Adalgisa Protonotari; Giuseppe Di Pasquale; Mirko Di Martino; Enrica Perrone; Paola Forti; Maria Pia Fantini
Journal:  Eur J Clin Pharmacol       Date:  2014-12-23       Impact factor: 2.953

4.  Assessing Concurrent Adherence to Combined Essential Medication and Clinical Outcomes in Patients With Acute Coronary Syndrome. A Population-Based, Real-World Study Using Group-Based Trajectory Models.

Authors:  Clara L Rodríguez-Bernal; Francisco Sánchez-Saez; Daniel Bejarano-Quisoboni; Isabel Hurtado; Anibal García-Sempere; Salvador Peiró; Gabriel Sanfélix-Gimeno
Journal:  Front Cardiovasc Med       Date:  2022-05-25

5.  Does treatment impact health outcomes for patients after acute coronary syndrome?

Authors:  Jelena Umbrasienė; Giedrius Vanagas; Jon Venclovienė
Journal:  Int J Environ Res Public Health       Date:  2015-05-29       Impact factor: 3.390

6.  Cognitive dysfunction and poor health literacy are common in veterans presenting with acute coronary syndrome: insights from the MEDICATION study.

Authors:  Lucas N Marzec; Evan P Carey; Anne C Lambert-Kerzner; Eric J Del Giacco; Stephanie D Melnyk; Chris L Bryson; Ibrahim E Fahdi; Hayden B Bosworth; Fran Fiocchi; P Michael Ho
Journal:  Patient Prefer Adherence       Date:  2015-06-08       Impact factor: 2.711

7.  Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus.

Authors:  Casper H Jørgensen; Gunnar H Gislason; Ole Ahlehoff; Charlotte Andersson; Christian Torp-Pedersen; Peter R Hansen
Journal:  BMC Cardiovasc Disord       Date:  2014-01-09       Impact factor: 2.298

8.  Prevalence and Access of Secondary Source Medication Data: Evaluation of the Southeastern Diabetes Initiative (SEDI).

Authors:  Bradi B Granger; Melodie Staton; Lindsay Peterson; Shelley A Rusincovitch
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2015-03-25

Review 9.  Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain.

Authors:  Alex de la Sierra; Xavier Pintó; Carlos Guijarro; José López Miranda; Daniel Callejo; Jesús Cuervo; Rudi Subirà; Marta Rubio
Journal:  Adv Ther       Date:  2015-10-26       Impact factor: 3.845

10.  Missing signposts on the roadmap to quality: a call to improve medication adherence indicators in data collection for population research.

Authors:  Bradi B Granger; Shelley A Rusincovitch; Suzanne Avery; Bryan C Batch; Ashley A Dunham; Mark N Feinglos; Katherine Kelly; Marjorie Pierre-Louis; Susan E Spratt; Robert M Califf
Journal:  Front Pharmacol       Date:  2013-11-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.